Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Clinical Trials Arena on MSN2d
Palatin’s UC therapy prompts clinical remission in a third of patients
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
In one dog breed, selection for utility may have selected for obesity
It turned out increased obesity risk in Labradors was linked to the same genes and mechanisms that cause obesity in humans.
Yahoo Finance5d
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug ...
Palatin reports ‘positive’ results from Phase 2 study of PL8177
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
What is HC Wainwright’s Forecast for RYTM Q1 Earnings?
Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...
News-Medical.Net12d
The Natural Molecule That Could Rival Ozempic
BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...
7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Palatin Technologies, Inc.: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...